Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities

被引：27

作者：

Zhang, Ning ^{[1
]}

Xiao, Xiao-he ^{[1
]}

机构：

[1] Army Gen Hosp, Med Ctr Chinese Peoples Liberat 5, Dept Liver Dis, Beijing 100039, Peoples R China

来源：

JOURNAL OF INTEGRATIVE MEDICINE-JIM | 2021年 / 19卷 / 04期

关键词：

Cancer; Immunotherapy; Traditional Chinese medicine; Risk prevention; Treatment pattern; TRADITIONAL CHINESE MEDICINE; HERB-DRUG INTERACTIONS; ADJUNCTIVE THERAPY; LUNG-CANCER; MANAGEMENT; INHIBITORS; SURVIVAL; GINSENG; SAFETY; STAGE;

D O I：

10.1016/j.joim.2021.03.005

中图分类号：

R [医药、卫生];

学科分类号：

10 ;

摘要：

Cancer immunotherapy has led to a new era of cancer treatment strategies, and transforming healthcare for cancer patients. Meanwhile, reports of immune-related adverse events have been increasing, greatly hindering the use of cancer immunotherapy. Traditional Chinese medicine (TCM), which has been widely used in Asian countries for thousands of years, is known to play a complementary role in the treatment of cancer. Taken in combined with conventional modern therapies, such as resection, ablation and radiotherapy, TCM exerts its main anti-cancer effects in two ways: health-strengthening (Fu-Zheng) and pathogen-eliminating (Qu-Xie). Theoretically, pathogen-eliminating TCM can promote the release of tumor-related antigens and should be able to increase the effect of immunotherapy, while health strengthening TCM may have immune-enhancing mechanisms that overlap with immunotherapy. In the era of cancer immunotherapy, it is important to balance the use of TCM and immunotherapy, with the goal of enhancing immune efficacy and antagonizing immune toxicity. In this article, we discuss this issue by considering the mechanism of tumor immunotherapy, alongside the theoretical basis of TCM treatment of tumors, with the aim of bringing new insights to future research in this field. (C) 2021 Shanghai Changhai Hospital. Published by ELSEVIER B.V. All rights reserved.

引用

页码：291 / 294

页数：4

共 36 条

[1] SnapShot: Immune Checkpoint Inhibitors [J].

Abril-Rodriguez, Gabriel ;

Ribas, Antoni .

CANCER CELL, 2017, 31 (06)

[2] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[3] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

[4] Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ [J].

Chen, Xingmeng ;

Chen, Xi ;

Gao, Junxiao ;

Yang, Han ;

Duan, Yue ;

Feng, Yuxin ;

He, Xin ;

Gong, Xiaoqun ;

Wang, Hanjie ;

Wu, Xiaoli ;

Chang, Jin .

FRONTIERS IN PHARMACOLOGY, 2019, 10

[5]

Davies M, 2017, IMMUNOTARGETS THER, V6, P51, DOI 10.2147/ITT.S141577

[6] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].

Eggermont, A. M. M. ;

Chiarion-Sileni, V. ;

Grob, J. -J. ;

Dummer, R. ;

Wolchok, J. D. ;

Schmidt, H. ;

Hamid, O. ;

Robert, C. ;

Ascierto, P. A. ;

Richards, J. M. ;

Lebbe, C. ;

Ferraresi, V. ;

Smylie, M. ;

Weber, J. S. ;

Maio, M. ;

Bastholt, L. ;

Mortier, L. ;

Thomas, L. ;

Tahir, S. ;

Hauschild, A. ;

Hassel, J. C. ;

Hodi, F. S. ;

Taitt, C. ;

de Pril, V. ;

de Schaetzen, G. ;

Suciu, S. ;

Testori, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855

[7]

Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756

[8] Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer [J].

Genova, Carlo ;

Rossi, Giovanni ;

Rijavec, Erika ;

Biello, Federica ;

Barletta, Giulia ;

Tagliamento, Marco ;

Grossi, Francesco .

EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) :573-585

[9] Ginseng (Panax ginseng Meyer) oligopeptides regulate innate and adaptive immune responses in mice via increased macrophage phagocytosis capacity, NK cell activity and Th cells secretion [J].

He, Li-Xia ;

Ren, Jin-Wei ;

Liu, Rui ;

Chen, Qi-He ;

Zhao, Jian ;

Wu, Xin ;

Zhang, Zhao-Feng ;

Wang, Jun-Bo ;

Pettinato, Giuseppe ;

Li, Yong .

FOOD & FUNCTION, 2017, 8 (10) :3523-3532

[10] Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer [J].

Hu, Xue-Qing ;

Sun, Yang ;

Lau, Eric ;

Zhao, Ming ;

Su, Shi-Bing .

CURRENT CANCER DRUG TARGETS, 2016, 16 (04) :346-356

← 1 2 3 4 →